Physician

Aasma Riaz, MD

According to 2025 Medicare claims, Aasma Riaz, MD (NPI: 1497981187) practices internal medicine in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is CITY HEALTHCARE, LLC (NPI: 1346740214; TIN: 822894531) and primary practice location at 34711-7012. Riaz is affiliated with the Pathways Accountable Care, LLC d/b/a Pathways Health Partners (ACO ID: D0048), participating under the REACH model.

Riaz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 315 traditional Medicare patients, billed 3,794 HCPCS/CPT codes, and received $301,278 in Medicare payments. The top billing code was G0439 (Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit). Part D data shows 11,267 prescription claims across 800 beneficiaries totaling $1,102,108 in drug costs, led by Ozempic (Semaglutide). DME data shows 296 claims. Open Payments data shows 35 records totaling $813. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $29,434 to $301,278. Similarly, Part D prescription costs have risen steadily, from $125,149 to $1,102,108. In contrast, DME billing represents a smaller volume and moved from a lower plateau to a higher plateau, from $2,266 to $29,702.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	236	845	$29,434
2016	184	959	$29,796
2017	145	540	$19,129
2018	157	728	$38,719
2019	215	1,229	$70,024
2020	276	2,075	$121,486
2021	328	3,264	$194,318
2022	363	3,176	$208,922
2023	301	3,480	$299,544
2024	315	3,794	$301,278

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	446	2,602	$125,149
2016	752	4,418	$187,059
2017	801	5,878	$271,059
2018	543	2,197	$109,739
2019	219	1,896	$117,488
2020	366	4,034	$272,654
2021	488	6,422	$473,193
2022	629	7,220	$610,487
2023	699	9,045	$888,635
2024	800	11,267	$1,102,108

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	16	$1,101
2016	N/R	44	$2,141
2017	N/R	28	$1,687
2018	N/R	16	$938
2019	89	144	$11,950
2020	72	117	$5,937
2021	17	86	$4,694
2022	13	198	$11,535
2023	N/R	119	$8,829
2024	34	296	$21,505

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0439	Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit	237	237	$126
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	301	1,078	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	154	276	$65
G0442	Annual alcohol misuse screening, 5 to 15 minutes	263	263	$18
G0444	Annual depression screening, 5 to 15 minutes	245	245	$18

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ozempic	Semaglutide	98	3,871	$124,667
Eliquis	Apixaban	73	5,613	$106,546
Mounjaro	Tirzepatide	52	2,308	$84,631
Jardiance	Empagliflozin	60	4,022	$77,207
Trulicity	Dulaglutide	45	1,820	$59,774

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4239	Supply allowance for non-adjunctive, non-implanted continuous glucose monitor (cgm), includes all supplies and accessories, 1 month supply = 1 unit of service	N	N/R	20	$9,922
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	66	$4,751
E0601	Continuous positive airway pressure (cpap) device	Y	N/R	49	$1,649
A7030	Full face mask used with positive airway pressure device, each	N	N/R	15	$1,202
A7031	Face mask interface, replacement for full face mask, each	N	N/R	15	$1,066

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	35	$813	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Aasma Riaz, MD?

Tedicare shows public-source Medicare data for Aasma Riaz, MD (NPI 1497981187), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Aasma Riaz, MD have ACO affiliation data?

Aasma Riaz, MD is shown with ACO affiliation data for Pathways Accountable Care, LLC d/b/a Pathways Health Partners (REACH, ACO ID D0048).

What billing organization is linked to Aasma Riaz, MD?

Aasma Riaz, MD is linked to CITY HEALTHCARE, LLC (billing NPI 1346740214) in the available physician profile data.

Does Aasma Riaz, MD have Open Payments data?

Aasma Riaz, MD has 35 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.